A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.

@article{LerouxRoels2012AP1,
  title={A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.},
  author={Isabel Leroux-Roels and Geert Leroux-Roels and Fr{\'e}d{\'e}ric Cl{\'e}ment and Pierre G Vandepapeli{\`e}re and Vassil Vassilev and Edouard Y Ledent and Thomas C. Heineman},
  journal={The Journal of infectious diseases},
  year={2012},
  volume={206 8},
  pages={
          1280-90
        }
}
BACKGROUND An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being developed for the prevention of herpes zoster and its complications. METHODS In a phase I/II, open-label, randomized, parallel-group study, older adults (50-70 years) received 2 doses 2 months apart of an adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 45), a live attenuated Oka strain VZV vaccine (OKA; n = 45), or HZ/su and OKA administered concomitantly (n = 45). To evaluate safety prior to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 49 CITATIONS

A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine

  • Applied Microbiology and Biotechnology
  • 2015
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011

Similar Papers

Loading similar papers…